Dual T/NK cell engagement via B7-H6-targeted bispecific antibodies and IL-15 eradicates chemo-resistant solid tumors
These findings establish B7-H6-targeted BsAbs combined with cytokine engineering as a viable strategy for treating refractory solid tumors.
Authors
- Xuqian Ma
- Mingqian Feng (ORCID: https://orcid.org/0000-0002-0654-8224)
- Dianbao Zuo (ORCID: https://orcid.org/0000-0002-7574-3808)
- Yuankui Zhu (ORCID: https://orcid.org/0000-0001-8000-9440)
- Huixia He (ORCID: https://orcid.org/0000-0002-2540-6918)
- Xin Chen (ORCID: https://orcid.org/0000-0002-9588-0164)
- Fanglin Wang (ORCID: https://orcid.org/0000-0002-9722-5446)
- Kangkang Ji
Institutions
- Shandong University of Aeronautics (CN)
- Huazhong Agricultural University (CN)
- Hubei University of Arts and Science (CN)
- Xiang Yang No.1 People's Hospital (CN)
- Hubei University of Technology (CN)
- Hubei University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-12
- DOI
- https://doi.org/10.3389/fimmu.2025.1625813
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Huazhong Agricultural University